115 related articles for article (PubMed ID: 11684551)
1. Intravenous iron sucrose: establishing a safe dose.
Chandler G; Harchowal J; Macdougall IC
Am J Kidney Dis; 2001 Nov; 38(5):988-91. PubMed ID: 11684551
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
3. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.
Macdougall IC; Roche A
Am J Kidney Dis; 2005 Aug; 46(2):283-9. PubMed ID: 16112047
[TBL] [Abstract][Full Text] [Related]
4. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
[TBL] [Abstract][Full Text] [Related]
7. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.
Schröder O; Schrott M; Blumenstein I; Jahnel J; Dignass AU; Stein J
Z Gastroenterol; 2004 Aug; 42(8):663-7. PubMed ID: 15314711
[TBL] [Abstract][Full Text] [Related]
8. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
9. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
10. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
11. Iron sucrose: the oldest iron therapy becomes new.
Yee J; Besarab A
Am J Kidney Dis; 2002 Dec; 40(6):1111-21. PubMed ID: 12460028
[TBL] [Abstract][Full Text] [Related]
12. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
15. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron in a primary-care clinic.
Maslovsky I
Am J Hematol; 2005 Apr; 78(4):261-4. PubMed ID: 15795917
[TBL] [Abstract][Full Text] [Related]
17. Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis.
Fenwick S; Peebles G
J Ren Care; 2011 Mar; 37(1):47-51. PubMed ID: 21288317
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
19. A rapid infusion protocol is safe for total dose iron polymaltose: time for change.
Garg M; Morrison G; Friedman A; Lau A; Lau D; Gibson PR
Intern Med J; 2011 Jul; 41(7):548-54. PubMed ID: 21040319
[TBL] [Abstract][Full Text] [Related]
20. Delayed adverse reactions to total-dose intravenous iron polymaltose.
Haines ML; Gibson PR
Intern Med J; 2009 Apr; 39(4):252-5. PubMed ID: 19402865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
